Saroglitazar · Lipaglyn
Small molecule
Evidence outlook
Approved: Type 2 diabetes mellitus, add-on to metformin (IN)
This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.
track record: Partial signal
Also in development:Type 2 DiabetesHypertriglyceridemia
Also approved (2)
- Type 2 diabetes mellitus, add-on to metformin
- Hypertriglyceridemia and diabetic dyslipidemia
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
EPICS-III NCT05133336 · Primary Biliary Cholangitis This was a randomized, quadruple-masked Phase 2/3 trial with 196 participants. Its primary endpoint was met according to the sponsor's announcement of 2025-08-29. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate. Registry: NCT05133336 | 2/3 | Proportion of subjects with biochemical response based on the composite endpoints of ALP and total bilirubin (From baseline to week 52) 2025-04-30 | Primary composite biochemical response at 52 weeks: treatment difference 48.5% favouring saroglitazar 1 mg over placebo (P<0.001) (2025-08-29). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Competitive landscape
This drug's own stage for Hypertriglyceridemia: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Saroglitazar (Lipaglyn): this drug | Stage not on record | Small molecule | PPAR-alpha/PPAR-gamma | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Acid Ethyl Esters A (Omtryg) | ApprovedUS marketing discontinued | Small molecule | Triglyceride synthesis / VLDL | not yet graded | No reviewed efficacy summary in this indication | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Olezarsen (Tryngolza) | Phase 3 | RNA / oligonucleotide | APOC3 | Reliable signal | NCT05552326: Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) NCT05079919: Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | |
| Pemafibrate (Parmodia) | Phase 3 | Small molecule | PPAR-alpha | Reliable signal | NCT04998981: n=344 randomized (of 353 enrolled per CT.gov). % change in fasting TG from baseline at Week 12: -34.1% (pemafibrate 0.2mg/d), -44.0% (pemafibrate 0.4mg/d), -30.5% (fenofibrate 200mg/d), +6.5% (placebo); 0.4mg/d vs placebo p<0.0001, vs fenofibrate p=0.0083. | |
| Plozasiran (Redemplo) | Phase 3 | RNA / oligonucleotide | APOC3 | Partial signal | NCT06347003: Primary endpoint met: triglyceride reduction vs placebo, and all prespecified secondary endpoints (SHASTA-3, Arrowhead, 2026-07-22). | |
| Pravafenix | Phase 3(overall) | Small molecule | HMG-CoA reductase / PPAR-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BW-00112 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2 | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-7249 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ION775 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| MAR001 | Phase 2 | Monoclonal antibody | ANGPTL4 | Weak signal | Featured results are safety only in this race | |
| RBD5044 | Phase 2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| SYH2070 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded | No reviewed efficacy summary in this indication | |
| Tipelukast | Phase 2 | Small molecule | Cysteinyl leukotriene receptor 1 (CysLT1) / PDE3 / PDE4 / 5-lipoxygenase | Weak signal | NCT02681055: Primary 1, cholesterol efflux capacity change from baseline to week 12: mean -0.013 (SD 0.1022) percentage of cholesterol. Primary 2, serum triglyceride change from baseline to week 8: mean -21.67 (SD 27.89) mg/dL. Single arm (n=19), no comparator; CT.gov posted results. | |
| TLC-2716 | Phase 2 | Small molecule | Liver X receptor (LXR) | not yet graded | No reviewed efficacy summary in this indication | |
| JMT202 | Phase 1/2 | Monoclonal antibody | β-Klotho (KLB) | not yet graded | No reviewed efficacy summary in this indication | |
| RN0361 | Phase 1/2 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-APOC3 | Phase 1(overall) | RNA / oligonucleotide | Apolipoprotein C-III (APOC3) | not yet graded | No reviewed efficacy summary in this indication | |
| ISH0688 | Phase 1 | Protein / enzyme therapeutic | FGF21 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Kylo-12 | Phase 1 | RNA / oligonucleotide | APOC3 | not yet graded | No reviewed efficacy summary in this indication | |
| VERVE-201 | Phase 1 | Gene therapy / editing | ANGPTL3 gene (hepatocyte genomic DNA) | not yet graded | No reviewed efficacy summary in this indication | |
| Omega-3-Carboxylic Acids (Epanova) | Discontinued | Small molecule | Peroxisome proliferator-activated receptor alpha (PPARα); also acts as a lipid-modifying agent via free fatty acid receptor | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Lipaglyn (Saroglitazar) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
2027 (1)
April 2027 (1)
What to watch
2028 (1)
July 2028 (1)
What to watch
2032 (1)
November 2032 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent